of day, air quality, and how many times it has been used through sensor technology on the device. The first smart-inhaler was approved in 2019 by the FDA, its purpose is to track patient use of the device and some other circumstantial factors that could affect the effectiveness of the dosage. This information is sent via Bluetooth to a mobile device app, and is later shared with their physician to determine what kind of things can trigger issues with asthma and other problems. This technology presents a great way to cut down on medical costs associated with asthma and also help patients better manage their condition with fewer emergencies. The Teva ProAir Digihaler was the first FDA approved smart inhaler. It shows how effective the device is at aiding patients in using the proper dose amount for their asthma. In a study published by the European Respiratory Journal, the ProAir Digihaler accurately identified when patients were using their inhalers and whether they were effectively administering the dose in a 370 patient trial with the device. This study further gives an overview on the technology regarding applications and devices that help aid in the tracking and medication management for asthma and other lung conditions. Another study showed that smart inhalers accurately recorded all doses administered by patients with their technology, which signifies their importance in providing accurate dosage information to patients and their physicians. Propellants In 2009, the FDA banned the use of inhalers that use chlorofluorocarbons (CFC) as propellants. In their place, inhalers now use hydrofluoroalkane (HFA). HFA is not environmentally inert as it is a greenhouse gas but it does not affect the ozone layer. While some people with asthma and advocacy groups contend that HFA inhalers are not as effective, published clinical studies indicate CFC and HFA inhalers are equally effective in controlling asthma. While the impact of CFCs from inhalers on the ozone layer had been minuscule (dwarfed by industrial processes using CFCs), the FDA in its interpretation of the Montreal Protocol mandated the switch in propellants. Patients expressed concern about the high price of the HFA inhalers as there are no generic versions, whereas generic CFC inhalers had been available. Proper use It is important to use proper technique when administering inhalers to self or others. Improper use of inhalers is very common, can lead to distribution of the medicine into the mouth or throat where